| Literature DB >> 31523421 |
Anna Machowska1, Jonatan Sparrentoft1, Cecilia StålsbyLundborg1, Megha Sharma1,2, Shyam Kumar Dhakaita3.
Abstract
BACKGROUND: Single-dose perioperative antibiotic prophylaxis (PAP) is recommended for clean, non-infectious surgeries to prevent surgical site infections. However, the common practice of unindicated use and prolonged use of antibiotics contributes to the development and spread of antibiotic resistance (ABR). The present study explores the perioperative use of antibiotics among inpatients with surgical indications at surgery departments of a teaching (TH) and a non-teaching (NTH) tertiary care hospital in Madhya Pradesh, India.Entities:
Keywords: Abdominal surgery; Empirical prescribing; Non-infectious surgery indications; Perioperative antibiotic prescribing; Urogenital surgery
Year: 2019 PMID: 31523421 PMCID: PMC6734588 DOI: 10.1186/s13741-019-0121-3
Source DB: PubMed Journal: Perioper Med (Lond) ISSN: 2047-0525
Fig. 1Diagrammatic representation of the analysis process of inpatients data from the surgery departments of two hospitals. PAP, perioperative antibiotic prophylaxis; TH, teaching hospital; NTH, non-teaching hospital
Inpatients’ characteristics at surgery departments of the TH and NTH in Madhya Pradesh, India
| All patients | UUTSI | LUTSI | RASI | EASI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TH, | NTH, | TH, | NTH, | TH, | NTH, | TH, | NTH, | TH, | NTH, | |
| Age in years | ||||||||||
| 0–17 |
| 377 (6) | 21 (7) | 36 (5) |
| 15 (2) |
| 26 (3) | 72 (15) | 91 (12) |
| 18–39 | 2018 (33) |
| 159 (56) | 425 (57) | 69 (9) | 119 (14) | 320 (23) |
| 239 (50) | 419 (55) |
| 40–59 | 1773 (29) | 1689 (27) | 78 (27) | 197 (27) | 150 (20) | 148 (18) | 453 (32) | 222 (30) | 108 (22) | 188 (25) |
| ≥ 60 |
| 1440 (23) | 26 (9) | 83 (11) | 484 (65) | 542 (66) | 482 (35) | 219 (29) | 63 (13) | 65 (8) |
| Male |
| 4384 (70) | 218 (77) | 546 (74) | 719 (96) | 812 (99) |
| 532 (71) | 347 (72) | 610 (80) |
| Female | 1570 (25) |
| 66 (23) | 195 (26) | 29 (4) | 12 (1) | 212 (15) |
| 135 (28) | 153 (20) |
| Patients prescribed AB | 5430 (88) | 5402 (86) | 251 (88) | 624 (84) | 748 (100) | 823 (100) |
| 628 (84) |
| 719 (94) |
| Total number of AB prescriptions (Np) | 12,213 | 9598 | 563 | 1055 | 1624 | 1453 | 2767 | 1240 | 1435 | 1679 |
| Prescriptions adherent to WHOLEM, Np (percentage of total nr. of prescriptions) |
| 4019 (42) |
| 346 (33) |
| 346 (24) |
| 510 (41) |
| 790 (47) |
| Prescriptions adherent to NLEMI, Np (percentage of total nr. of prescriptions) |
| 5487 (57) | 342 (61) | 592 (56) |
| 592 (41) |
| 734 (59) |
| 984 (59) |
| Average length of hospital stay, days [SD] |
| 4.6 [3.9] |
| 3.8 [3.2] |
| 5.0 [3.2] |
| 5.1 [4.0] |
| 6.3 [5.3] |
| Average length of AB treatment, days [SD] |
| 4.4 [3.2] |
| 3.6 [2.6] |
| 4.9 [3.0] |
| 4.4 [3.4] |
| 5.5 [4.0] |
| AB prescribed for 1 day | 36 (1) | 221 (7) | 7 (2) | 96 (13) | 6 (1) | 44 (5) | 14 (1) | 41 (5) | 9 (2) | 40 (5) |
| DDD/100 patient days | 72.5 |
| 89.5 |
| 84.6 |
| 78.3 |
| 74.9 |
|
| Total nr. of AB doses administered | 65,288 | 28,600 | 2759 | 2950 | 9415 | 4733 | 13,890 | 4060 | 6270 | 7980 |
| Total nr. of AB doses prescribed using generic names |
| 1716 (6) |
| 118 (4) |
| 142 (3) |
| 203 (5) |
| 399 (5) |
| Total nr. of AB doses administered parenterally | 34,613 (53) |
| 1335 (41) |
| 3672 (39) |
| 8195 (59) |
| 4582 (75) |
|
Variables are presented either with percentages or standard deviations in parenthesis. Percentages were rounded off to integers, and standard deviations were rounded off to one decimal. Percentages are presented in parenthesis, and standard deviations in square brackets. Abbreviations: AB antibiotic, DDD defined daily dose, EASI emergency abdominal surgery indications, Np total number of antibiotic prescriptions, nr. number, LUTSI lower urinary tract surgery indications, NLEMI National List of Essential Medicines of India, NTH non-teaching hospital, RASI routine abdominal surgery indications, SD standard deviation, TH teaching hospital, UUTSI upper urinary tract surgery indications, WHOLEM WHO List of Essential Medicines
a Significantly larger p-values
Classification of surgery inpatients in four selected diagnoses groups, based on their diagnoses
| Diagnosis groups (ICD-10 codes) | TH, | NTH, |
|---|---|---|
| Upper urinary tract surgery indications (UUTSI) | 284 (10) [100] |
|
| Kidney/ureter calculi (N20) | 280 [99] |
|
| Other | 4 [32] | 7 [1] |
| Lower urinary tract surgery indications (LUTSI) | 748 (26) [100] | 824 (27) [100] |
| Benign prostate hyperplasia (N40) | 522 [70] | 558 [68] |
| Urethral/bladder calculi (N21) | 89 [12] |
|
| Urethral stricture (N35) | 85 [11] | 66 [8] |
| Prostate cancer (C61) | 29 [4] | 30 [4] |
| Bladder cancer (C67) | 10 [1] | 10 [1] |
| Urethral disease* (N36) | 9 [1] | 10 [1] |
| Other | 4 [< 1] | 8 [< 1] |
| Routine abdominal surgery indications (RASI) |
| 748 (24) [100] |
| Hernia (K40-K46) |
| 312 [42] |
| Other gastric/duodenal disease (K31) | 113 [8] | 151 [20] |
| Biliary calculi (K80) | 73 [5] | 110 [15] |
| Anal fissure/fistula (K60) |
| 30 [4] |
| Malignancy in GI-tract (C15-C26) | 78 [6] | 51 [7] |
| Cholecystitis (K81) | 30 [2] | 43 [6] |
| Anal abscess (K61) | 10 [< 1] | 28 [4] |
| Other disease in anal region** (K62) | 10 [< 1] | 8 [1] |
| Colon polyposis (K63.2) | 9 [< 1] | 5 [< 1] |
| Other | 3 [< 1] | 10 [< 1] |
| Emergency abdominal surgery indications (EASI) | 482 (17) [100] |
|
| Appendicitis (K35-K37) | 268 [56] |
|
| Intestinal obstruction (K56) | 132 [27] | 202 [27] |
| Peritonitis (K56) | 80 [17] | 99 [13] |
| Other | 2 [< 1] | 3 [< 1] |
Numbers of patients with percentages rounded off to the nearest whole number. Abbreviations: TH teaching hospital, ns p value value not significant, NTH non-teaching hospital
*Urethral disease includes fistulas, diverticulosis, carbuncles, and prolepses of the urethra
**Disease in the anal/rectal region includes polyps, stenosis, wounds, bleedings, and prolapses in the anal/rectal region
a Significantly larger p-values
Antibiotic prescribing patterns in four surgical diagnoses groups at surgery departments of the TH and NTH
| UUTSI | LUTSI | RASI | EASI | |||||
|---|---|---|---|---|---|---|---|---|
| TH, | NTH, | TH, | NTH, | TH, | NTH, | TH, | NTH, | |
| Tetracyclines (J01A), | 32 (6) | 2 (< 1) | 50 (3) | 0 | 233 (8) | 6 (< 1) | 98 (7) | 2 (< 1) |
| Amphenicols (J01B), | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Penicillins (J01C), | 17 (3) | 42 (4) | 77 (5) | 80 (6) | 219 (8) | 80 (6) | 131 (9) | 147 (9) |
| Penicillins with extended spectrum (J01CA), | 3 (18) | 2 (5) | 5 (6) | 4 (5) | 21 (10) | 16 (20) | 0 | 10 (7) |
| Penicillins combinations including enzyme inhibitors (J01CR), | 14 (82) | 40 (95) | 72 (94) | 76 (95) | 198 (90) | 64 (80) | 131 (100) | 137 (93) |
| Other beta-lactam antibiotics (J01D), | 70 (12) | 239 (23) | 220 (14) | 191 (13) | 535 (19) | 332 (27) | 218 (15) | 296 (18) |
| First-generation cephalosporins J01DB, | 19 (27) | 7 (3) | 49 (22) | 1 (< 1) | 149 (28) | 17 (5) | 50 (23) | 11 (4) |
| Second-generation cephalosporins J01 DC, | 0 | 9 (4) | 13 (6) | 24 (13) | 23 (4) | 41 (12) | 5 (2) | 29 (10) |
| Third-generation cephalosporins J01DD, | 51 (72) | 222 (93) | 158 (72) | 166 (87) | 363 (68) | 272 (82) | 162 (74) | 254 (86) |
| Fourth-generation cephalosporins J01DE, | 0 | 1 (< 1) | 0 | 0 | 0 | 1 (< 1) | 0 | 0 |
| Carbapenems J01DH, | 0 | 0 | 0 | 0 | 0 | 1 (< 1) | 1 (< 1) | 2 (< 1) |
| Sulfonamids and trimethoprim (J01E), | 11 (2) | 0 | 85 (5) | 0 | 100 (4) | 0 | 16 (1) | 0 |
| Macrolids and lincosamids (J01F), | 38 (7) | 0 | 180 (11) | 2 (< 1) | 405 (15) | 3 (< 1) | 94 (7) | 8 (< 1) |
| Macrolids (J01FA), | 0 | 0 | 4 (2) | 0 | 3 (< 1) | 0 | 1 (1) | 0 |
| Lincosamids (J01FF), | 38 (100) | 0 | 176 (98) | 2 (100) | 402 (99) | 3 | 93 (99) | 8 (100) |
| Aminoglycosides (J01G), | 76 (13) | 269 (26) | 328 (20) | 449 (31) | 486 (18) | 250 (20) | 189 (13) | 225(13) |
| Quinolones (J01 M), | 216 (38) | 281 (27) | 609 (38) | 543 (37) | 315 (11) | 114 (9) | 263 (18) | 145 (9) |
| Fixed-dose combinations (J01R), | 3 (1) | 160 (15) | 22 (1) | 155 (11) | 37 (1) | 298 (24) | 17 (1) | 399 (24) |
| Quinolones and imidazole derivatives*, | 0 | 2 (1) | 0 | 17 (11) | 0 | 26 (9) | 0 | 22 (6) |
| Cephalosporins and enzyme inhibitors, | 3 (100) | 158 (99) | 22 (100) | 138 (89) | 37 | 272 (91) | 17 (100) | 377 (94) |
| Other antibiotics (J01X), | 100 (18) | 62 (6) | 53 (3) | 33 (2) | 437 (16) | 157 (13) | 408 (28) | 457 (27) |
| Imidazole derivatives (J01XD)**, | 100 (100) | 62 (97) | 53 (100) | 31 (94) | 437 (100) | 157 (100) | 408 (100) | 453 (99) |
| Other antibiotics (J01XX), | 0 | 2 (3) | 0 | 2 (6) | 0 | 0 | 0 | 4 (1) |
EASI emergency abdominal surgery indications, LUTSI lower urinary tract surgery indications, N total number of prescriptions in the diagnosis group, n number of prescriptions for the third-level ATC pharmacological sub-group, RASI routine abdominal surgery indications, UUTSI upper urinary tract surgery indications, x number of prescriptions for the fourth-level ATC pharmacological sub-group. Percentages were rounded and presented in parenthesis
*Fixed-dose combinations that were not assigned by WHOCC, a fourth level ATC-code
**The imidazole derivate group also included oral metronidazole categorized as P01AB01
Fig. 2Proportions of inpatients prescribed antibiotics in selected non-infectious surgical diagnoses groups (a to d) in two study hospitals. Numbers in graphs indicate percentages of patients and are rounded off to nearest integers. AB, antibiotics; N, total number of prescriptions in the diagnosis group; n, number of prescriptions for the third-level ATC pharmacological sub-group; TH, teaching hospital; NTH, non-teaching hospital